Stroke 2017 Feb 17. Epub 2017 Feb 17.
From the University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom (Y.B., H.D., A.S., G.Y.H.L.); Cardiovascular Center, Beijing Tongren Hospital, Capital Medical University, China (Y.B.); Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Science, Guangzhou, China (H.D.); and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark (G.Y.H.L.).
Background And Purpose
: This study was designed to evaluate the effectiveness and safety of rivaroxaban in real-world practice compared with effectiveness and safety of dabigatran or warfarin for stroke prevention in atrial fibrillation through meta-analyzing observational studies.Methods
: Seventeen studies were included after searching in PubMed for studies reporting the comparative effectiveness and safety of rivaroxaban versus dabigatran (n=3), rivaroxaban versus Warfarin (n=11), or both (n=3) for stroke prevention in atrial fibrillation.Results
: Overall, the risks of stroke/systematic thromboembolism with rivaroxaban were similar when compared with those with dabigatran (stroke/thromboembolism: hazard ratio, 1. Read More